In today’s briefing:
- Sai Life Sciences Pre-IPO – Portfolio Expansion and Increased Production Capacity to Drive Growth
- Cyberdyne (7779 Jp) – Improving Financial Discipline
- GRCE: aSAH KOL Summary
- Inventurus Pre-IPO – Accelerating Growth with Major Aquity Acquisition
- Vivos Therapeutics, Inc. – New Strategic Model & Key Regulatory Milestones Provide Revenue Tailwind
Sai Life Sciences Pre-IPO – Portfolio Expansion and Increased Production Capacity to Drive Growth
- SAI Life Sciences (SAILS12 IN) is looking to raise up to US$360m in its upcoming India IPO.
- Sai Life Sciences is a contract research, development and manufacturing organisation providing end-to-end services across drug discovery, development and manufacturing value-chain, for small to global pharmaceutical innovators and biotechnology firms.
- In this note, we talk about the company’s historical performance.
Cyberdyne (7779 Jp) – Improving Financial Discipline
- The company recorded a significant decline in operating losses in Q1-2 FY3/25, driven by reductions in R&D and Head Office costs.
- Sales growth was relatively low at 1.9% YoY, with 18.9% growth YoY in the Americas driven by the Treatment service segment offsetting declines in other regions.
- The Medical HAL Lower Limb Type saw 6.1% rental sales growth YoY, with Japan seeing the strongest growth at 12.3% YoY.
GRCE: aSAH KOL Summary
- Grace is a clinical-stage, biotechnology company focused on rare disease.
- Its lead program, GTX-104, is a novel injectable formulation of nimodipine for the treatment of aneurysmal subarachnoid hemorrhage (aSAH).
- Other programs include GTX-102 for Ataxia Telangiectasia & GTX-101 for postherpetic neuralgia.
Inventurus Pre-IPO – Accelerating Growth with Major Aquity Acquisition
- Inventurus Knowledge Solutions (IKSINCD IN) is looking to raise up to US$295m in its upcoming India IPO.
- IKS is a technology-enabled healthcare solutions provider, assisting physician enterprises in US, Canada and Australia. It is a one-stop shop designed to handle physicians administrative tasks.
- In this note, we look at the firm’s past performance.
Vivos Therapeutics, Inc. – New Strategic Model & Key Regulatory Milestones Provide Revenue Tailwind
- Medtech focused on obstructive sleep apnea (OSA) treatment.
- Vivos commercializes proprietary oral appliances and support services for the treatment of OSA and associated conditions of dentofacial abnormalities, including snoring, temporomandibular joint dysfunction (TMD), and bruxism.
- The company’s Complete Airway Repositioning and/or Expansion (CARE) oral devices are patient preferred over market-leading CPAPs and have key FDA clearances that provide a competitive advantage over other oral appliances.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
